An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2009
At a glance
- Drugs BL 1020 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 15 Sep 2008 Planned end date identified as 1 Dec 2007 from ClinicalTrials.gov.
- 15 Sep 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 05 Feb 2008 Interim results reported in a BioLineRx media release.